BioSpace News Archive

Sonnet BioTherapeutics Holdings, Inc. announced today that Lori McNeill has been appointed to the Company’s Board of Directors.

Tryp Therapeutics, Inc. today announced the filing of two new provisional patent applications.

Outlook Therapeutics, Inc. today announced it will present at Eyecelerator @ AAO 2022 taking place Thursday, September 29, 2022 in Chicago, Illinois.

Neuronetics, Inc. announced upgrades to the TrakStar® platform that will offer all NeuroStar® providers a more turnkey patient management experience.

Paratek Pharmaceuticals, Inc. today announces that the company will host an update for investors on the global opportunity for NUZYRA® (omadacycline) in non-tuberculous mycobacteria (NTM) on Monday, Oct. 3.

Biofrontera Inc. announced that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has awarded the previously nominated Ameluz® marketing campaign, created by Biofrontera Inc. along with Elevate Healthcare, “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year” awards.

Whitsett Vision Group announced it is the first ophthalmologist group in the country to perform cataract surgeries using a new lens approved by the Food and Drug Administration and that the practice has added another lens to its patient offerings.

Y-mAbs Therapeutics, Inc. today announced that Adium Pharma S.A. (“Adium”) has submitted a regulatory filing for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine receptors for the treatment of major unmet medical needs, achieved positive in vivo data for PNV-5030, as a potential treatment for chronic pain.

Nanjing Bioheng Biotech Co., Ltd today announced that a phase I clinical study results of RD13-01, an anti-CD7 universal CAR-T therapy product, have been published in the reputable academic journal, Cell Research.